Neoplasms by Histologic Type: Clinical Trials

43,590 trials for Neoplasms by Histologic Type, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18671 completed, 6544 recruiting, 6127 unknown, 4926 terminated. 18006 Phase 2, 11654 Phase 1, 5427 Not applicable, 3955 Phase 3, 844 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 218006Completed 7728, Recruiting 2509, Terminated 2507, Unknown 2187, Active not recruiting 1423, Withdrawn 768, Not yet recruiting 758, Suspended 85, Enrolling by invitation 41
Phase 111654Completed 5170, Terminated 1891, Recruiting 1662, Unknown 1051, Active not recruiting 883, Withdrawn 552, Not yet recruiting 333, Suspended 87, Enrolling by invitation 25
Not applicable5427Completed 2097, Unknown 1021, Recruiting 998, Terminated 390, Not yet recruiting 367, Active not recruiting 276, Withdrawn 212, Enrolling by invitation 39, Suspended 27
Phase 33955Completed 1707, Unknown 621, Recruiting 540, Terminated 400, Active not recruiting 380, Not yet recruiting 168, Withdrawn 114, Suspended 13, Enrolling by invitation 12
Early Phase 1844Completed 225, Recruiting 162, Unknown 152, Terminated 103, Not yet recruiting 82, Active not recruiting 58, Withdrawn 49, Suspended 9, Enrolling by invitation 4
Phase 4767Completed 332, Unknown 207, Recruiting 82, Terminated 54, Not yet recruiting 40, Active not recruiting 25, Withdrawn 22, Enrolling by invitation 5

Follow Neoplasms by Histologic Type: new trials by email Literature Review of Neoplasms by Histologic Type trials Research Report on Neoplasms by Histologic Type

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma
administration of axitinib in combination with etoposide - Medulloblastoma, Ependymoma
Phase 1 / Phase 2RecruitingAssistance Publique Hopitaux De Marseille402032-02-012026-11-12
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma
Phase 2WithdrawnActuate Therapeutics Inc.2030-12-182022-02-22
FLASH Pilot Phase 1 Safety Study
IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma
Not applicableNot yet recruitingLesley A. Jarvis102029-10-312026-05-27
A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas
RNS System Implantation - Glioma, Glioma Intracranial
Not applicableNot yet recruitingMedical College of Wisconsin32028-08-012026-10-13
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Phase 3Not yet recruitingAmgen5602028-06-302026-09-15
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease
Phase 1 / Phase 2Not yet recruitingJubilant Therapeutics Inc.1132028-04-012026-08-07
Pyronaridine in Acute Myeloid Leukemia (AML)
Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 2SuspendedArmaceutica, Inc.2002028-02-212026-10-19
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors
Not applicableNot yet recruitingUniversity of Vermont Medical Center332028-02-012026-08-25
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1Not yet recruitingGerman Cancer Research Center122028-01-012025-03-14
Methadone as an Alternative Treatment for Children Underdoing HSCT
PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia
Phase 3SuspendedUniversity of Texas Southwestern Medical Center602028-01-012025-10-23
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML)
Phase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer Center582027-12-012026-08-25
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 2Not yet recruitingExcyte Biopharma Ltd642027-12-012026-11-06
Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms
Clinical Intervention or Procedure, Electronic Health Record Review, Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas - Pancreatic Neoplasm, Pancreatic Neuroendocrine Tumor
Not applicableEnrolling by invitationOhio State University Comprehensive Cancer Center122027-10-012026-10-13
Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor
Pimicotinib, Tumor resection surgery - Tenosynovial Giant Cell Tumor, Diffuse
Phase 2Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine842027-10-012026-07-16
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
Chimeric Antigen Receptor (CAR) Therapy Infusion, Bevacizumab (Avastin) - Neuroblastoma (NBL), Ewing Sarcoma
Phase 1Not yet recruitingUniversität Münster302027-10-012026-11-03
Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)
Tarlatamab - High-Grade Glioma (HGG)
Phase 1Not yet recruitingVall d'Hebron Institute of Oncology102027-10-012026-11-12
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma
Not applicableNot yet recruitingJonsson Comprehensive Cancer Center1002027-09-022026-10-19
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma
Individual Exercise, Group Exercise - Multiple Myeloma
Not applicableSuspendedMedical University of Vienna452027-09-012026-10-09
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Phase 2Not yet recruitingXiang-Qian1202027-09-012026-08-27
Family-Focused Study to Support Medication for Opioid Use Disorder
FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate
Not applicableNot yet recruitingUniversity of Wisconsin, Madison3382027-08-312026-07-07

Showing 20 of 43590. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (3675)  ·  Leukemia, Myeloid, Acute (3593)  ·  Carcinoma, Hepatocellular (3384)  ·  Melanoma (3203)  ·  Lymphoma (3018)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2522)  ·  Leukemia (2382)  ·  Lymphoma, Non-Hodgkin (2287)  ·  Neoplasms (2153)  ·  Glioblastoma (2076)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2018)  ·  Carcinoma, Renal Cell (1964)  ·  Squamous Cell Carcinoma of Head and Neck (1959)  ·  Recurrence (1912)  ·  Lymphoma, Follicular (1875)

Broader conditions

Neoplasms (41437)  ·  Neoplasms by Site (19113)  ·  Neoplasms, Glandular and Epithelial (18857)  ·  Hemic and Lymphatic Diseases (18097)  ·  Immune System Diseases (14280)  ·  Immunoproliferative Disorders (13969)  ·  Lymphoproliferative Disorders (13871)  ·  Carcinoma (13273)  ·  Hematologic Diseases (12057)  ·  Lymphatic Diseases (11264)  ·  Neoplasms, Nerve Tissue (8922)  ·  Neoplasms, Germ Cell and Embryonal (8670)  ·  Neuroectodermal Tumors (8519)  ·  Pathological Conditions, Signs and Symptoms (8002)

Interventions

Cyclophosphamide (2271)  ·  Rituximab (1453)  ·  Dexamethasone (1404)  ·  Radiotherapy (1288)  ·  Cisplatin (1284)  ·  pembrolizumab (1141)  ·  Cytarabine (1120)  ·  Doxorubicin (1004)  ·  Etoposide (938)  ·  Vincristine (923)  ·  fludarabine (897)  ·  Lenalidomide (896)  ·  Carboplatin (884)  ·  Nivolumab (881)  ·  Gemcitabine (819)

Sponsors

National Cancer Institute (NCI) (1898)  ·  M.D. Anderson Cancer Center (1210)  ·  Memorial Sloan Kettering Cancer Center (725)  ·  Sun Yat-sen University (559)  ·  Novartis Pharmaceuticals (468)  ·  Mayo Clinic (381)  ·  Children's Oncology Group (362)  ·  Dana-Farber Cancer Institute (322)  ·  Pfizer (302)  ·  City of Hope Medical Center (290)  ·  Fred Hutchinson Cancer Center (282)  ·  Bristol-Myers Squibb (272)  ·  Hoffmann-La Roche (266)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (256)  ·  Washington University School of Medicine (245)

Countries

United States (21238)  ·  China (6873)  ·  France (4174)  ·  Italy (3130)  ·  Canada (2880)  ·  Germany (2864)  ·  United Kingdom (2678)  ·  Spain (2630)  ·  Australia (1995)  ·  South Korea (1779)  ·  Netherlands (1630)  ·  Belgium (1530)  ·  Poland (1173)  ·  Japan (1112)  ·  Taiwan (1105)

Results publications

PMID 34515338, PMID 31401903, PMID 41671463, PMID 37146227, PMID 32499241, PMID 35622074, PMID 40135712, PMID 32632956, PMID 40812353, PMID 36648215, PMID 37185961, PMID 30207593, PMID 34398557, PMID 31150573, PMID 33538338, PMID 12049862, PMID 25057165, PMID 25667295, PMID 27238653, PMID 28410911, PMID 32827353, PMID 33394722, PMID 40550489, PMID 24383844, PMID 25527568, PMID 29433850, PMID 33242441, PMID 33357481, PMID 38502198, PMID 39319495, PMID 39563886, PMID 11981766, PMID 19097774, PMID 19192962, PMID 20375404, PMID 23524640, PMID 26373676, PMID 28054442, PMID 31221778, PMID 31395089, PMID 35235189, PMID 35829925, PMID 36064577, PMID 36184192, PMID 37022569, PMID 37192741, PMID 37505794, PMID 38620092, PMID 12540794, PMID 18650514

NIH funding

2023 (358), 2018 (207), P30CA033572 (202), 2016 (197), 2017 (184), 2015 (182), 2019 (180), U10CA032102 (175), 2014 (163), 2025 (153), P30CA015704 (148), P30CA015083 (142), 2009 (136), P30CA016672 (125), U10CA098543 (124)